# New clinical trials in Serbia: 187 since Nov 2024

Updated November 6, 2026.

187 clinical studies with a site in Serbia were first posted on ClinicalTrials.gov from November 12, 2024 to November 6, 2026; 118 have an industry sponsor and 113 are recruiting or about to. The newest, NCT07923253, was posted on November 6, 2026: Prospective Study of TVRFA Treatment for FIGO Type 3-5 Uterine Fibroids (University of Novi Sad).

## The full list

New clinical trials with a site in Serbia: 187 rows for $9.35, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 4 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/country/serbia

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 187
- Industry sponsored: 118
- Recruiting or not yet: 113
- Latest posted: November 6, 2026

## Newest trials

The newest 100 of 187, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07923253 | Prospective Study of TVRFA Treatment for FIGO Type 3-5 Uterine Fibroids | University of Novi Sad | Not applicable | Active not recruiting | Leiomyoma (Uterine Fibroids) | 50 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923253) |
| October 29, 2026 | NCT07903259 | Effect of Paracetamol Administration Timing on Oxidative Stress in Children Undergoing Sevoflurane Anesthesia | University of Belgrade | Phase 4 | Completed | Oxidative Stress, Sevoflurane Anaesthesia | 49 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903259) |
| October 21, 2026 | NCT07886749 | Corrective Multisport Training | University of Novi Sad | Not applicable | Completed | Postural Alignment, Posture | 398 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07886749) |
| October 21, 2026 | NCT07885891 | Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia | Wockhardt | Phase 3 | Not yet recruiting | Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP) | 324 | Bosnia and Herzegovina, Bulgaria, Croatia, France, Georgia, Greece, India... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885891) |
| October 15, 2026 | NCT07876180 | Effects of High-Intensity Interval Training and Exercise Snacking on Glycemic Control and Cardiorespiratory Fitness in Adults With Type 2... | University of Nis | Not applicable | Completed | Typ 2 Diabetes | 60 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876180) |
| October 14, 2026 | NCT07874139 | Prospective Study on Antimicrobial RESIstance in Chronic Pulmonary DiseasE | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Observational | Recruiting | Chronic Lung Diseases | 683 | Albania, Australia, Belgium, Brazil, Canada, China, Croatia, Czechia, Denmark... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874139) |
| September 29, 2026 | NCT07845487 | A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis | Palisade Bio | Phase 2 | Recruiting | Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis | 204 | Canada, Czechia, France, Georgia, Hungary, Italy, Latvia, Poland, Romania... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845487) |
| August 28, 2026 | NCT07793149 | Comparison of KIRA Hydrating Treatment and Jet Peel for Facial Skin Hydration | Faculty of Pharmacy Novi Sad | Not applicable | Completed | Facial Skin Hydration, Skin Rejuvenation | 23 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793149) |
| August 27, 2026 | NCT07791069 | International Multicenter Outcomes of Transcatheter Pulmonary Flow Restrictors in Congenital and Acquired Heart Disease | Fondation Hôpital Saint-Joseph | Observational | Enrolling by invitation | Congenital Heart Disease | 150 | France, Germany, Serbia, United Arab Emirates, United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791069) |
| August 27, 2026 | NCT07789015 | A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Idiopathic Inflammatory Myopathies | 270 | Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czechia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789015) |
| August 24, 2026 | NCT07783399 | The Effects of Carnitine Supplementation on Oocytes in Women Undergoing IVF Process | The Obstetrics and Gynaecology Clinic Narodni Front | Not applicable | Recruiting | Infertility (IVF Patients) | 70 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783399) |
| August 10, 2026 | NCT07753993 | A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. | AstraZeneca | Phase 3 | Recruiting | Chronic Kidney Disease | 7,000 | Argentina, Australia, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753993) |
| August 4, 2026 | NCT07745504 | A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | Novo Nordisk A/S | Phase 3 | Recruiting | Overweight, Obesity | 285 | Greece, Hungary, Portugal, Serbia, Sweden, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07745504) |
| August 4, 2026 | NCT07743918 | Vitamin D Status and Clinical Outcomes in Locally Advanced Cervical Cancer | University of Kragujevac | Observational | Recruiting | Locally Advanced Cervical Cancer, Vitamin D Concentration | 100 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743918) |
| July 20, 2026 | NCT07715474 | ALIGN-ACS Pilot Study | HeartBeam, Inc. | Observational | Active not recruiting | Acute Coronary Syndromes | 120 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715474) |
| July 17, 2026 | NCT07709949 | Does Daily Physical Education Improve Motor Skill Development and Health-Related Physical Fitness in Preschool Children? | University of Novi Sad | Not applicable | Completed | Motor Activity, Motor Coordination, Child Development, Excercise, Physical Education and Training/Methods | 323 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709949) |
| July 13, 2026 | NCT07698951 | Evaluating Percutaneous Repair Of The Atrial Septum With A Novel PFO Occluder: The PROTEA-PFO OUS Study | Recross Cardio, Inc. | Not applicable | Recruiting | PFO, PFO - Patent Foramen Ovale, Cryptogenic Stroke, Patent Foramen Ovale, PFO-associated Stroke | 15 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07698951) |
| July 9, 2026 | NCT07691970 | Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From... | AstraZeneca | Phase 3 | Recruiting | Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus | 1,072 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691970) |
| July 6, 2026 | NCT07685379 | A Study Comparing Real and Sham Repetitive Transcranial Magnetic Stimulation in Adults With Fibromyalgia, Assessing Effects on Pain... | Institute of Rheumatology, Serbia | Not applicable | Completed | Fibromyalgia Syndrome | 30 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07685379) |
| July 6, 2026 | NCT07683325 | NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's... | Agomab Spain S.L.U. | Phase 2 | Recruiting | Fibrostenotic Crohn's Disease | 320 | Serbia, United Kingdom, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07683325) |
| June 30, 2026 | NCT07677059 | A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study | Kymera Therapeutics, Inc. | Phase 2 | Recruiting | Asthma (Diagnosis) | 264 | Germany, Poland, Serbia, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07677059) |
| June 26, 2026 | NCT07671963 | Bone Substitutes and NIPSA in Intrabony Periodontal Defects: A Randomized Controlled Trial | University of Belgrade | Not applicable | Recruiting | Periodontitis (Stage 3), Minimally Invasive Surgical Procedures, Bone Substitutes | 30 | Italy, Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07671963) |
| June 17, 2026 | NCT07655388 | Wound Healing, Dressing Type, and Dressing Change Frequency in THA | Clinical Center of Vojvodina | Not applicable | Recruiting | Wound Healing Time, Total Hip Arthroplasty (THA) | 90 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07655388) |
| June 17, 2026 | NCT07652294 | Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD | Spyre Therapeutics, Inc. | Phase 2 | Enrolling by invitation | Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative | 645 | Argentina, Australia, Austria, Belgium, Brazil, Chile, Czechia, Georgia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07652294) |
| June 15, 2026 | NCT07647406 | Intraseptal and Periodontal Ligament Anaesthesia for Tooth Extraction in Patients With Type 2 Diabetes | University of Business Academy in Novi Sad, Serbia | Not applicable | Completed | Diabetes Mellitus Type 2 | 120 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07647406) |
| June 8, 2026 | NCT07633288 | A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With... | SynAct Pharma Aps | Phase 2 | Recruiting | Respiratory Viral Infection | 96 | Bosnia and Herzegovina, Montenegro, New Zealand, Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07633288) |
| June 5, 2026 | NCT07630714 | A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to \< 18 Years... | AstraZeneca | Phase 2 | Recruiting | Systemic Lupus Erythematosus | 24 | Australia, Belgium, Chile, Israel, Japan, Netherlands, Peru, Philippines... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630714) |
| June 4, 2026 | NCT07625644 | BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) | SystImmune Inc. | Phase 3 | Recruiting | Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung... | 550 | Australia, Bulgaria, Canada, Czechia, France, Georgia, Germany, Greece... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07625644) |
| June 1, 2026 | NCT07618676 | The 50:50 Nitrous Oxide vs 2% Lidocaine Challenge | Institute for Oncology and Radiology of Serbia | Not applicable | Completed | Acute Pain, Anxiety, Central Venous Catheter | 62 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07618676) |
| June 1, 2026 | NCT07618130 | Opioid-Free Anesthesia and Pain Study in Cardiac Surgery Patients | Clinical Centre of Serbia | Not applicable | Not yet recruiting | Posoperativ Pain, Chronich Pain, Postoperativ Delirum, Opoid-free Managment | 400 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07618130) |
| May 8, 2026 | NCT07576686 | AI-Guided CBT for Depression and Anxiety | Aleksandra Stojanovic | Not applicable | Recruiting | Depression - Major Depressive Disorder, Anxiety Disorders | 120 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07576686) |
| May 7, 2026 | NCT07574099 | Loading Protocols for Dental Implants Placed in Healed Fully Edentulous Maxilla | University of Belgrade | Not applicable | Active not recruiting | Maxilla, Tooth Loss / Rehabilitation | 24 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07574099) |
| April 30, 2026 | NCT07559903 | ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety) | Emory University | Observational | Recruiting | Coronary Artery Disease | 5,000 | Germany, Serbia, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559903) |
| April 14, 2026 | NCT07527741 | A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment... | Hoffmann-La Roche | Observational | Recruiting | Early-stage HER2+ Breast Cancer | 100 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527741) |
| April 13, 2026 | NCT07525375 | A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in... | AstraZeneca | Phase 2 | Recruiting | Asthma | 69 | Argentina, Czechia, Hungary, Mexico, Poland, Serbia, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07525375) |
| March 31, 2026 | NCT07503873 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative... | TG Therapeutics, Inc. | Phase 2 | Recruiting | Multiple Sclerosis | 350 | Bosnia and Herzegovina, Georgia, North Macedonia, Poland, Serbia, Ukraine | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503873) |
| March 24, 2026 | NCT07491666 | Effects of Neuromuscular Exercises on Motor Skills in Girls | University of Novi Sad | Not applicable | Completed | Motor Skills, Locomotor Activity, Objective Control Skills | 79 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07491666) |
| March 20, 2026 | NCT07485933 | Comparison of Cerebral Oximetry and Neurological Status Testing in the Awake Patient in the Detection of Cerebral Ischemia During Carotid... | Clinic for Vascular and Endovascular Surgery, University Clinical Center of Serbia | Not applicable | Active not recruiting | Carotid Arteriosclerosis, Near Infrared Spectroscopy | 160 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07485933) |
| March 19, 2026 | NCT07483827 | A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy | eleva GmbH | Phase 1 | Recruiting | C3 Glomerulopathy (C3G), Healthy Adult Participants | 39 | Austria, Belgium, Czechia, France, Greece, Latvia, Lithuania, Netherlands... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07483827) |
| March 18, 2026 | NCT07481409 | A Strategy for Fall Prevention in Aging Women | University of Novi Sad | Not applicable | Completed | Fall Prevention, Functional Independence, Balance Impairment | 32 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07481409) |
| March 17, 2026 | NCT07477587 | A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With... | Shanghai Henlius Biotech | Phase 1 | Recruiting | Multiple Myeloma (MM) | 258 | Australia, China, Georgia, Serbia, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07477587) |
| March 17, 2026 | NCT07476326 | Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma | Biocon Biologics UK PLC | Phase 1 | Recruiting | Melanoma | 120 | Brazil, Chile, Georgia, Moldova, Romania, Serbia, South Africa, Spain, Turkey... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07476326) |
| March 16, 2026 | NCT07473700 | Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease | Tectonic Operating Company, Inc. | Phase 2 | Recruiting | Hypertension, Pulmonary, Lung Diseases, Interstitial | 25 | Poland, Romania, Serbia, South Korea, Spain, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07473700) |
| February 27, 2026 | NCT07438496 | A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus | Janssen Research & Development, LLC | Phase 3 | Recruiting | Lupus Erythematosus, Systemic | 600 | Argentina, Australia, Brazil, Bulgaria, China, Czechia, Denmark, Finland... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07438496) |
| February 23, 2026 | NCT07425990 | FET-LET-2x2: Clinical Pregnancy Rates After Frozen Embryo Transfer in Natural and Modified Natural Cycles | University of Novi Sad | Not applicable | Recruiting | Infertility Female, Frozen Embryo Transfer (FET) | 120 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07425990) |
| February 19, 2026 | NCT07421986 | Elastic Band Exercise to Improve Hip Strength and Agility in Young Basketball Players | Nebojša Trajković | Not applicable | Completed | Eccentric Exercise Training, Strength Training Effects, Strengthening Exercises, Hip Adduction Strength, Healthy... | 21 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421986) |
| February 18, 2026 | NCT07416721 | Cooling of the Knee After Total Knee Arthroplasty | Clinical Center of Vojvodina | Not applicable | Completed | Osteoarthritis, Knee, Total Knee Replacement | 99 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07416721) |
| February 17, 2026 | NCT07415044 | LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis | Eli Lilly and Company | Phase 2 | Recruiting | Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe | 1,431 | Argentina, Brazil, Canada, China, Colombia, Croatia, Czechia, France, Greece... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07415044) |
| February 17, 2026 | NCT07414433 | Validation of Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma | University of Belgrade | Observational | Not yet recruiting | Hepatocellular Carcinoma (HCC), Liver Neoplasms | 60 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07414433) |
| February 17, 2026 | NCT07414420 | Oral Dynamic Propulsion Appliance in Treatment of Patients With Obstructive Sleeping Apnea | University of Belgrade | Not applicable | Not yet recruiting | Obstructive Sleep Apnea (OSA) | 40 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07414420) |
| February 13, 2026 | NCT07410065 | Supersaturated Hydrogen-Rich Water for Outpatients With Persistent Excess Weight | Center for Health Sciences, Serbia | Not applicable | Not yet recruiting | Overweight | 120 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410065) |
| February 13, 2026 | NCT07409181 | A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) | Boehringer Ingelheim | Phase 2 | Recruiting | Systemic Lupus Erythematosus | 405 | Argentina, Australia, Brazil, Bulgaria, China, Colombia, Croatia, Germany... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07409181) |
| February 13, 2026 | NCT07409103 | A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate... | Elevara Medicines Limited | Phase 2 | Recruiting | Active Rheumatoid Arthritis | 180 | Serbia, South Africa, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07409103) |
| February 12, 2026 | NCT07405840 | Application of Autologous Stem Cells From Adipose Tissue in the Regeneration of Knee Joint Cartilage | Clinical Center of Vojvodina | Phase 4 | Active not recruiting | Osteearthritis | 60 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07405840) |
| February 10, 2026 | NCT07401381 | A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone... | Rovi Pharmaceuticals Laboratories | Phase 1 | Recruiting | Hormone Receptor Positive Early Breast Cancer | 120 | Serbia, Spain, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07401381) |
| February 9, 2026 | NCT07395219 | European TIF2.0 Registry | Cleveland Clinic London | Observational | Enrolling by invitation | Gastro -Oesophagal Reflux, Laryngo-pharyngeal Reflux | 500 | Austria, Italy, Serbia, Switzerland, Turkey (Türkiye), United Arab Emirates... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07395219) |
| February 6, 2026 | NCT07393789 | A Multicomponent Physical Activity Intervention Effect on Weekly Steps and Physical Fitness in Preadolescents | University of Belgrade | Not applicable | Completed | Multicomponent 16-week Program Comprised of a Goal Setting, Wearable Activity Tracker Feedback, Physical Exercising... | 178 | Czechia, Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07393789) |
| February 6, 2026 | NCT07391813 | SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer | SN BioScience | Phase 1/2 | Recruiting | Patient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell... | 55 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07391813) |
| February 4, 2026 | NCT07387575 | Screening in Relatives With Elevated Risk for Unruptured Intracranial Aneurysms | University of Novi Sad | Observational | Enrolling by invitation | Intracranial Aneurysms, Subarachnoid Hemorrhage, Aneurysmal | 300 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07387575) |
| January 30, 2026 | NCT07378709 | Exploratory Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma | University of Belgrade | Observational | Recruiting | Hepatocellular Carcinoma (HCC), Liver Neoplasms | 15 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07378709) |
| January 26, 2026 | NCT07366684 | Clinical Characteristics, Frailty, and Prognostic Predictors in Patients Aged 75 and Older With Acute Coronary Syndrome | Clinical Center Niš | Observational | Recruiting | ST Elevation (STEMI) Myocardial Infarction, Non ST Elevation Myocardial Infarction (NSTEMI), Unstable Angina Pectoris | 550 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07366684) |
| January 22, 2026 | NCT07360899 | Atrial Fibrillation TRIal of Left Atrial Appendage Closure Using Seralene Hemostatic Suture | Institute of Cardiovascular Diseases, Vojvodina | Not applicable | Recruiting | ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION, Atrial Fibrillation (AF), Mitral Valve Surgery, Stroke (in Patients... | 200 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07360899) |
| January 22, 2026 | NCT07359846 | A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) | Generate Biomedicines | Phase 3 | Recruiting | Severe Asthma | 786 | Argentina, Australia, Belgium, Estonia, France, Georgia, India, Ireland, Italy... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07359846) |
| January 22, 2026 | NCT07357740 | A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes | Novo Nordisk A/S | Phase 2 | Withdrawn | Diabetes Mellitus, Type 2 | 0 | Denmark, Greece, Malaysia, Serbia, Slovakia, Spain, Thailand, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07357740) |
| January 20, 2026 | NCT07351149 | Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery | Uppsala University | Observational | Recruiting | Acute Kidney Injury | 2,000 | Australia, Brazil, Canada, Croatia, France, Italy, Netherlands, Serbia, Sweden... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07351149) |
| January 20, 2026 | NCT07349953 | Correlation Between Anthropometric Characteristics and Age-based Formulas for Uncuffed Pediatric Endotracheal Tube | Mother and Child Health Institute of Serbia Dr Vukan Cupic | Observational | Completed | Endotracheal Tube, Finger | 103 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07349953) |
| January 13, 2026 | NCT07337759 | Fetus Programming and Long Active Outcomes, Interaction Between Mother, Placenta and Fetus in Perinatal and Methabolic... | University of Belgrade | Observational | Completed | Placental Insufficiency Hypertensive Disorders of Pregnancy Diabetes Mellitus in Pregnancy Thrombophilia in Pregnancy... | 440 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07337759) |
| January 9, 2026 | NCT07328906 | Steroid Treatment to Prevent Thoracic Endovascular Aortic Repair Postimplantation Syndrome | University of Belgrade | Not applicable | Not yet recruiting | Postimplantation Syndrome, Myocardial Injury, MACE, Mortality | 174 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07328906) |
| January 7, 2026 | NCT07323654 | A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma | Kymera Therapeutics, Inc. | Phase 2 | Recruiting | Eosinophilic Asthma | 264 | Argentina, Austria, Belgium, Germany, Italy, Poland, Romania, Serbia, Slovakia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07323654) |
| January 5, 2026 | NCT07317830 | Effects of Different Vitamin D3 Formulations in Vitamin D-Deficient Adults | Center for Health Sciences, Serbia | Not applicable | Recruiting | Vitamin D Deficiency | 20 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07317830) |
| December 26, 2025 | NCT07304843 | A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With... | Umecrine Cognition AB | Phase 1/2 | Completed | Primary Biliary Cholangitis (PBC) | 207 | Germany, Greece, Hungary, Italy, Serbia, Spain, Turkey (Türkiye), United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07304843) |
| December 24, 2025 | NCT07301736 | Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma | Chiesi Farmaceutici S.p.A. | Phase 2 | Recruiting | Asthma | 780 | Argentina, Bosnia and Herzegovina, Bulgaria, Czechia, Germany, Hungary, Latvia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301736) |
| December 23, 2025 | NCT07299019 | A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis | Zenas BioPharma (USA), LLC | Phase 3 | Recruiting | Secondary Progressive Multiple Sclerosis | 990 | Australia, Belgium, Bulgaria, Croatia, Czechia, Estonia, France, Georgia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07299019) |
| December 22, 2025 | NCT07296315 | Confirmatory Clinical Study in Active Ulcerative Colitis | MRM Health NV | Phase 2 | Recruiting | Colitis, Ulcerative | 204 | Czechia, Georgia, Moldova, Poland, Serbia, Ukraine, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07296315) |
| December 17, 2025 | NCT07288489 | Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require... | VarmX B.V. | Phase 3 | Recruiting | Blood Loss, Surgical, Coagulation Disorder | 800 | Australia, Austria, Belgium, Bulgaria, Canada, France, Germany, Hungary, Italy... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07288489) |
| December 17, 2025 | NCT07288216 | Transition to KPL-387 Monotherapy Dosing & Administration Study | Kiniksa Pharmaceuticals International, plc | Phase 2 | Recruiting | Recurrent Pericarditis, Heart Diseases, Pericarditis | 120 | Canada, France, Germany, Greece, Italy, Poland, Serbia, Spain, United Kingdom... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07288216) |
| December 17, 2025 | NCT07287189 | Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | Satellos Bioscience, Inc. | Phase 2 | Active not recruiting | Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases, Muscular Dystrophies | 51 | Australia, Belgium, Canada, Poland, Serbia, Spain, United Kingdom, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07287189) |
| December 16, 2025 | NCT07285226 | Creatine HCl Supplementation in Sarcopenia: A Randomized Controlled Study | Center for Health Sciences, Serbia | Not applicable | Recruiting | Sarcopenia | 30 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285226) |
| December 16, 2025 | NCT07284459 | Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis | Contineum Therapeutics | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis | 324 | Argentina, Australia, Belgium, Canada, Chile, Denmark, France, Germany, Greece... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284459) |
| December 9, 2025 | NCT07272694 | Split Crest Procedure: Is It Necessary to Fill the Gap? | Vladimir Biocanin | Not applicable | Completed | Alveolar Bone Resorption, Alveolar Bone Grafting, Bone Expansion | 24 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07272694) |
| December 5, 2025 | NCT07267949 | Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation | Acesion Pharma | Phase 2 | Recruiting | Atrial Fibrillation (AF) | 200 | Bulgaria, Denmark, Germany, Hungary, Italy, Netherlands, Poland, Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07267949) |
| December 2, 2025 | NCT07258706 | Demographic and Interpopulation Variations in Evaluation and Results of TAVI | Poznan University of Medical Sciences | Observational | Enrolling by invitation | Aortic Stenosis, TAVI(Transcatheter Aortic Valve Implantation), Computed Tomography, Inflammatory Response During... | 800 | Italy, Poland, Serbia, Thailand, Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07258706) |
| December 2, 2025 | NCT07257666 | Sensory Deficit Following ACL Reconstruction: PRF Pilot Study | University of Belgrade | Observational | Completed | Anterior Cruciate Ligament Injury, Knee Injuries, Sensory Disorders, Bone-Patellar Tendon-Bone Autograft, Platelet-Rich... | 53 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07257666) |
| November 28, 2025 | NCT07253285 | A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight | Novo Nordisk A/S | Phase 3 | Recruiting | Overweight, Obesity | 460 | Australia, Austria, Belgium, Bulgaria, China, Colombia, Croatia, Denmark... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07253285) |
| November 26, 2025 | NCT07251933 | A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries | Takeda | Observational | Completed | Hereditary Angioedema (HAE) | 37 | Argentina, France, Germany, Israel, Serbia, United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07251933) |
| November 26, 2025 | NCT07250750 | A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis | ImmunAbs Inc. | Phase 1/2 | Recruiting | Myasthenia Gravis | 96 | Bulgaria, Italy, Poland, Serbia, Spain, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07250750) |
| November 25, 2025 | NCT07249333 | Perioperative Complications After Neoadjuvant Radiotherapy for Colorectal Cancer | Oncology Institute of Vojvodina | Observational | Recruiting | Colorectal Cancer, Neoadjuvant Radiotherapy, Perioperative Complication | 80 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07249333) |
| November 21, 2025 | NCT07241390 | A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney... | Eli Lilly and Company | Phase 3 | Recruiting | Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease | 7,140 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07241390) |
| November 17, 2025 | NCT07230288 | Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis | AbbVie | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis | 165 | Australia, Bulgaria, Canada, France, Germany, Greece, Japan, Poland, Portugal... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07230288) |
| November 13, 2025 | NCT07227818 | Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia | Neurocrine Biosciences | Phase 3 | Recruiting | Schizophrenia | 560 | Puerto Rico, Serbia, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07227818) |
| October 20, 2025 | NCT07218029 | A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) | Merck Sharp & Dohme LLC | Phase 3 | Active not recruiting | Pulmonary Arterial Hypertension | 815 | Argentina, Australia, Belgium, Brazil, Canada, Colombia, Croatia, Czechia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07218029) |
| October 8, 2025 | NCT07212270 | Effectiveness of Intraseptal Anesthesia for Periodontal Surgical Procedures | University of Belgrade | Not applicable | Active not recruiting | Periodontitis, Gingivitis and Periodontal Diseases | 60 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07212270) |
| October 8, 2025 | NCT07211633 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in... | TG Therapeutics, Inc. | Phase 3 | Active not recruiting | Relapsing Multiple Sclerosis | 360 | Bosnia and Herzegovina, Bulgaria, Croatia, Czechia, Georgia, Hungary, North... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07211633) |
| October 2, 2025 | NCT07204886 | Impact of Multicomponent and Stability Training on Fitness and Function in Active Older Women | University of Novi Sad | Not applicable | Completed | Body Composition, Physical Fitness, Functional Capacities | 40 | Serbia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07204886) |
| September 29, 2025 | NCT07196501 | A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Neurocrine Biosciences | Phase 3 | Recruiting | Major Depressive Disorder | 550 | Australia, Bulgaria, Canada, Estonia, Italy, Poland, Serbia, South Korea... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07196501) |
| September 26, 2025 | NCT07194850 | A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) | argenx | Phase 2/3 | Recruiting | Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura, Immune... | 24 | France, Germany, Italy, Japan, Lithuania, Poland, Romania, Serbia, Spain... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07194850) |
| September 23, 2025 | NCT07188844 | An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Immunovant Sciences GmbH | Phase 2 | Terminated | Chronic Inflammatory Demyelinating Polyneuropathy | 26 | Argentina, Belgium, Brazil, Germany, Greece, Italy, Poland, Romania, Serbia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07188844) |
| September 22, 2025 | NCT07185009 | A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative... | Sanofi | Phase 3 | Recruiting | Ulcerative Colitis | 751 | Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Chile, China... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07185009) |
| September 22, 2025 | NCT07184996 | An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis | Sanofi | Phase 3 | Recruiting | Ulcerative Colitis | 980 | Argentina, Australia, Austria, Bulgaria, Canada, China, Czechia, France... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07184996) |
| September 22, 2025 | NCT07184944 | A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease | Sanofi | Phase 3 | Recruiting | Crohn's Disease | 751 | Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07184944) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| University of Belgrade | 12 | October 29, 2026 |
| University of Novi Sad | 11 | November 6, 2026 |
| AstraZeneca | 6 | August 10, 2026 |
| AbbVie | 5 | November 17, 2025 |
| Neurocrine Biosciences | 5 | November 13, 2025 |
| Sanofi | 5 | September 22, 2025 |
| Boehringer Ingelheim | 4 | August 27, 2026 |
| Clinical Center of Vojvodina | 4 | June 17, 2026 |
| argenx | 4 | September 26, 2025 |
| Immunovant Sciences GmbH | 4 | September 23, 2025 |
| University of Novi Sad, Faculty of Sport and Physical Education | 4 | May 13, 2025 |
| Novo Nordisk A/S | 3 | August 4, 2026 |
| Center for Health Sciences, Serbia | 3 | February 13, 2026 |
| University of Kragujevac | 2 | August 4, 2026 |
| Kymera Therapeutics, Inc. | 2 | June 30, 2026 |
| Spyre Therapeutics, Inc. | 2 | June 17, 2026 |
| Hoffmann-La Roche | 2 | April 14, 2026 |
| TG Therapeutics, Inc. | 2 | March 31, 2026 |
| Eli Lilly and Company | 2 | February 17, 2026 |
| Institute of Cardiovascular Diseases, Vojvodina | 2 | January 22, 2026 |

## Conditions

| Condition group | New trials | Latest |
| --- | --- | --- |
| [Colitis, Ulcerative](https://specstream.ai/data/clinical-trials/condition/colitis-ulcerative) | 8 | September 29, 2026 |
| [Asthma](https://specstream.ai/data/clinical-trials/condition/asthma) | 5 | June 30, 2026 |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 5 | September 23, 2025 |
| [Heart Failure](https://specstream.ai/data/clinical-trials/condition/heart-failure) | 5 | April 20, 2025 |
| [Inflammatory Bowel Diseases](https://specstream.ai/data/clinical-trials/condition/inflammatory-bowel-diseases) | 4 | September 29, 2026 |
| [Obesity](https://specstream.ai/data/clinical-trials/condition/obesity) | 4 | August 4, 2026 |
| [Lung Diseases, Interstitial](https://specstream.ai/data/clinical-trials/condition/lung-diseases-interstitial) | 4 | March 16, 2026 |
| [Stroke](https://specstream.ai/data/clinical-trials/condition/stroke) | 4 | February 4, 2026 |
| Myasthenia Gravis | 4 | November 26, 2025 |
| [Autoimmune Diseases](https://specstream.ai/data/clinical-trials/condition/autoimmune-diseases) | 4 | September 23, 2025 |
| [Hypertension](https://specstream.ai/data/clinical-trials/condition/hypertension) | 4 | September 18, 2025 |
| Colitis | 3 | September 29, 2026 |
| [Renal Insufficiency, Chronic](https://specstream.ai/data/clinical-trials/condition/renal-insufficiency-chronic) | 3 | August 10, 2026 |
| [Overweight](https://specstream.ai/data/clinical-trials/condition/overweight) | 3 | August 4, 2026 |
| [Acute Coronary Syndrome](https://specstream.ai/data/clinical-trials/condition/acute-coronary-syndrome) | 3 | July 20, 2026 |
| [Diabetes Mellitus, Type 2](https://specstream.ai/data/clinical-trials/condition/diabetes-mellitus-type-2) | 3 | June 15, 2026 |
| [Lupus Erythematosus, Systemic](https://specstream.ai/data/clinical-trials/condition/lupus-erythematosus-systemic) | 3 | June 5, 2026 |
| [Anxiety Disorders](https://specstream.ai/data/clinical-trials/condition/anxiety-disorders) | 3 | June 1, 2026 |
| [Atrial Fibrillation](https://specstream.ai/data/clinical-trials/condition/atrial-fibrillation) | 3 | January 22, 2026 |
| [Schizophrenia](https://specstream.ai/data/clinical-trials/condition/schizophrenia) | 3 | November 13, 2025 |
| Purpura, Thrombocytopenic, Idiopathic | 3 | September 26, 2025 |
| [Carcinoma, Non-Small-Cell Lung](https://specstream.ai/data/clinical-trials/condition/carcinoma-non-small-cell-lung) | 3 | September 4, 2025 |
| [Pulmonary Disease, Chronic Obstructive](https://specstream.ai/data/clinical-trials/condition/pulmonary-disease-chronic-obstructive) | 3 | May 20, 2025 |
| Myositis | 2 | August 27, 2026 |
| Vitamin D Deficiency | 2 | August 4, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 55 | October 21, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 49 | November 6, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 39 | September 29, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 27 | October 14, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 6 | February 6, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 5 | September 26, 2025 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 4 | March 19, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 2 | October 29, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).